Pediatric Brain Tumor Consortium

Pediatric Brain Tumor Consortium
Name	Pediatric Brain Tumor Consortium
Founded	1999
Type	Medical research consortium
Headquarters	United States
Fields	Pediatric oncology, neuro-oncology

Pediatric Brain Tumor Consortium is a multi-institutional clinical trials network focused on pediatric neuro-oncology, created to accelerate translational research and early-phase therapeutic trials for childhood brain tumors. The Consortium links major academic centers, pediatric hospitals, regulatory agencies, and philanthropic foundations to coordinate protocol development, biospecimen banking, and outcome assessment across North America and internationally. It operates within a landscape that includes major entities such as National Cancer Institute, St. Jude Children's Research Hospital, Dana–Farber Cancer Institute, Johns Hopkins Hospital, and Children's Hospital of Philadelphia while interacting with regulators like the Food and Drug Administration and funders like the American Cancer Society.

History

The Consortium was established in 1999 amid a period of increasing collaboration exemplified by networks such as Children's Oncology Group, COG Neuro-Oncology Committee, European Society for Paediatric Oncology, and initiatives fostered by the National Institutes of Health and National Cancer Institute. Early efforts drew on precedent from cooperative groups including Cancer and Leukemia Group B, Eastern Cooperative Oncology Group, and consortia developed at institutions like Memorial Sloan Kettering Cancer Center and Hospital for Sick Children. Milestones in the Consortium’s development coincided with broader shifts in pediatric oncology driven by discoveries at laboratories led by figures associated with Dana Farber Cancer Institute, Cold Spring Harbor Laboratory, and Broad Institute. Over time the Consortium has responded to advances in molecular pathology traced to projects such as The Cancer Genome Atlas, International Cancer Genome Consortium, and translational platforms at Fred Hutchinson Cancer Research Center.

Organization and Membership

The Consortium's membership comprises pediatric oncology centers including St. Jude Children's Research Hospital, Children's Hospital Boston, Children's Hospital of Philadelphia, Seattle Children's Hospital, and Texas Children's Hospital, with investigators drawn from university departments at Harvard Medical School, Johns Hopkins University School of Medicine, University of California, San Francisco School of Medicine, University of Toronto, and Columbia University Vagelos College of Physicians and Surgeons. Governance includes steering committees with representation from institutional review boards at Mayo Clinic, Yale School of Medicine, and University of Michigan Medical School, and protocol oversight by experts linked to American Society of Clinical Oncology and Society for Neuro-Oncology. Membership also integrates laboratory partners from Massachusetts Institute of Technology, Stanford University School of Medicine, University of Pennsylvania Perelman School of Medicine, and pediatric pathology cores with ties to Children's National Hospital.

Research Programs and Clinical Trials

Research spans early-phase trials, biomarker discovery, and molecularly targeted therapeutics, drawing on platforms developed in programs like Pediatric MATCH, ACNS trial series, and projects influenced by discoveries from Salk Institute for Biological Studies, Cold Spring Harbor Laboratory, and Broad Institute. Trials evaluate agents ranging from targeted inhibitors discovered in laboratories at Dana–Farber Cancer Institute to immunotherapies pioneered at Memorial Sloan Kettering Cancer Center and vaccine approaches investigated at Fred Hutchinson Cancer Research Center. Programs include tissue banking coordinated with biorepositories at National Cancer Institute, molecular profiling collaborations with Genentech, and imaging protocols aligned with standards from Radiological Society of North America. The Consortium also runs pilot studies that interface with pediatric precision oncology efforts like AACR GENIE and translational initiatives associated with Wellcome Trust–funded consortia.

Major Contributions and Findings

The Consortium has contributed to characterization of molecular subgroups for tumors such as medulloblastoma, ependymoma, and diffuse intrinsic pontine glioma, building on taxonomy advances from The Cancer Genome Atlas, International Cancer Genome Consortium, and studies originating at St. Jude Children's Research Hospital and SickKids Research Institute. Findings have informed risk stratification approaches employed by groups like Children's Oncology Group and therapeutic strategies shaped by work at Dana–Farber Cancer Institute and Johns Hopkins Hospital. The Consortium’s trials have generated data on targeted agents related to pathways discovered at Broad Institute and Cold Spring Harbor Laboratory, and on immunotherapy strategies paralleled by research at Memorial Sloan Kettering Cancer Center and Fred Hutchinson Cancer Research Center.

Collaborations and Partnerships

The Consortium partners with regulatory and funding organizations such as the National Cancer Institute, Food and Drug Administration, U.S. Department of Health and Human Services, and philanthropic entities including the St. Baldrick's Foundation and Alex's Lemonade Stand Foundation. Scientific collaborations extend to academic centers like Harvard Medical School, Stanford University, University of Toronto, and international groups such as European Society for Paediatric Oncology and research programs supported by the Wellcome Trust and European Commission. Industry partnerships have included pharmaceutical and biotechnology firms with histories of pediatric oncology drug development, and cooperative relationships with biobanks and informatics projects aligned with AACR initiatives.

Funding and Governance

Funding derives from a mix of federal grants through the National Cancer Institute, institutional support from participating hospitals such as St. Jude Children's Research Hospital and Children's Hospital of Philadelphia, philanthropic grants from American Cancer Society and St. Baldrick's Foundation, and sponsored research agreements with industry partners including biotechnology companies and foundations tied to translational research. Governance is overseen by a steering committee with representation from academic leaders at Johns Hopkins University, Harvard Medical School, University of California, San Francisco, and regulatory liaisons from National Institutes of Health and Food and Drug Administration, while ethical oversight involves institutional review boards at centers such as Mayo Clinic and Yale School of Medicine.

Category:Pediatric oncology